[Long-term efficacy of plasma-derived hepatitis B vaccine among Chinese children--a 12-year follow-up].
To evaluate protective efficacy of a plasma-derived hepatitis B vaccine during 12 years after vaccination. A 12-year follow-up of 350 children who participated a randomized, double blind, placebo-controlled trial in 1982. During the 12 years after vaccination, more vaccinated children had anti-HBs of 10 S/N ratios or more than did the controls. At the 12 years 46.1% of the vaccinated and 33.9% of the controls retained anti-HBs levels of S/N ratios > or = 10 (P < 0.05). However, at 12 years median S/N ratio of anti-HBs of the vaccinated children with detectable anti-HBs was lower than that of the controls (15 vs 36, P < 0.0001). Protective efficacy against HBsAg carriage status at 5-10 years after vaccination varied from 83% to 100%. At 12 years, 14 chronic HBsAg carriers were identified among the controls, whereas only 1 case was noted in the vaccinated group (7.6% vs 0.6%, P < 0.01), account for an efficacy of 92%. Protective efficacy against chronic HBsAg carriage was satisfactory at 12 years after vaccination. No evidence was showed to support a booster of hepatitis B vaccine at this time.